Evolution of Clinical Pharmacy in the Practice of Rheumatology

2006marked the 40thyearof publication for TheAnnals. Throughout its history, TheAnnalshas provided important contributions to the development of clinical pharmacy. In 2007, we arecontinuing to publish articles reflecting on the history of clinical pharmacy through theeyesof practitioners, including those pioneering clinical pharmacy, as wellas thosewho havemore recentlyentered the profession anda well-established specialty. In addition, we are presenting articles and editorials fromthe earlyhistory of TheAnnalsthathavegiven direction andshape to the practice of clinical pharmacy (seepage 1712).

[1]  J. Esdaile,et al.  Improving osteoarthritis detection in the community: pharmacist identification of new, diagnostically confirmed osteoarthritis. , 2007, Arthritis and rheumatism.

[2]  J. Sim,et al.  Effectiveness of community physiotherapy and enhanced pharmacy review for knee pain in people aged over 55 presenting to primary care: pragmatic randomised trial , 2006, BMJ : British Medical Journal.

[3]  F. Pucino,et al.  Use of biologics in rheumatoid arthritis: where are we going? , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[4]  B. Resman-Targoff Medical therapy: where are we now? , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[5]  T. Moger,et al.  Interview of patients by pharmacists contributes significantly to the identification of drug‐related problems (DRPs) , 2006, Pharmacoepidemiology and drug safety.

[6]  P. Richette,et al.  Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol , 2006, Nature Clinical Practice Rheumatology.

[7]  J. Cooper,et al.  Pharmacist interventions in geriatric nursing facility NSAID therapy: a one-year follow-up study of costs and outcomes. , 2005, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[8]  J. Brouwers,et al.  A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable? , 2005, Annals of the rheumatic diseases.

[9]  R. Fleischmann Is there a need for new therapies for rheumatoid arthritis? , 2005, The Journal of rheumatology. Supplement.

[10]  P. Lipsky,et al.  New concepts in the treatment of rheumatoid arthritis. , 2003, Annual review of medicine.

[11]  J. Stoner,et al.  Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[12]  S. Mehta,et al.  Health outcomes assessment in community pharmacy practices: a feasibility project. , 2002, Arthritis and rheumatism.

[13]  S. Dedhiya,et al.  Use of Point‐of‐Service Health Status Assessments by Community Pharmacists to Identify and Resolve Drug‐Related Problems in Patients with Musculoskeletal Disorders , 2001, Pharmacotherapy.

[14]  L. Callahan,et al.  The Arthritis Foundation 1948-1998: 50 years of arthritis care and research. , 1998, Arthritis care and research : the official journal of the Arthritis Health Professions Association.

[15]  Luis A. Rodriguez Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. , 1998 .

[16]  E. Kay The changing role of the clinical pharmacist in rheumatology. , 1986, British journal of rheumatology.

[17]  R. O. Day Variability in response to NSAIDs: what progress? , 1993, Agents and actions. Supplements.

[18]  Methotrexate in rheumatoid arthritis. Health and Public Policy Committee, American College of Physicians. , 1987, Annals of internal medicine.